RESUMEN

BACKGROUND: WC and NS contributed equally. Non-tuberculous mycobacteria (NTM) frequently colonise patients with end stage cystic fibrosis (CF), but its impact on the course of the disease following lung transplantation is unknown. METHODS: Lung transplant recipients with CF who underwent lung transplantation at our institution between January 1990 and May 2003 (n=146) and CF patients awaiting lung transplantation in May 2003 (n=31) were studied retrospectively. RESULTS: The prevalence rate of NTM isolated from respiratory cultures in patients with end stage CF referred for lung transplantation was 19.7%, compared with a prevalence rate of 13.7% for NTM isolates in CF lung transplant recipients. The overall prevalence of invasive NTM disease after lung transplantation was low (3.4%) and was predicted most strongly by pre-transplant NTM isolation (p=0.001, Fisher's exact test, odds ratio (OR) 6.13, 95% CI 3.2 to 11.4). This association was restricted to Mycobacterium abscessus (p = 0.005, Fisher's exact test, OR 7.45, 95% CI 2.9 to 16.9). While NTM disease caused significant morbidity in a small number of patients after transplantation, it was successfully treated and did not influence the post-transplant course of the disease. CONCLUSION: The isolation of NTM before transplantation in CF patients should not be an exclusion criterion for lung transplantation, but it may alert the clinician to patients at risk of recurrence following transplantation.

Asunto(s)

RESUMEN

BACKGROUND: A modified Phase I/II trial was conducted evaluating the incorporation of three-dimensional conformal radiation therapy into a strategy of sequential and concurrent carboplatin/paclitaxel in Stage III unresectable nonsmall cell lung carcinoma (NSCLC). The dose of thoracic conformal radiation therapy (TCRT) from 60 to 74 gray (Gy) was increased. Endpoints included response rate, toxicity, and survival. METHODS: Sixty-two patients with unresectable Stage III NSCLC were included. Patients received 2 cycles of induction carboplatin (area under the concentration curve [AUC], 6) and paclitaxel (225 mg/m(2) over 3 hours) every 21 days. On Day 43, concurrent TCRT and weekly (x 6) carboplatin (AUC, 2) and paclitaxel (45 mg/m(2)/3 hours) were initiated. The TCRT dose was escalated from 60 to 74 Gy in 4 cohorts (60, 66, 70, and 74 Gy). RESULTS: The response rate to induction carboplatin/paclitaxel was 40%. Eight patients (13%) progressed on the induction phase. No dose-limiting toxicity was observed during the escalation of the TCRT dose from 60 to 74 Gy. The major toxicity was esophagitis, however, only 8% developed Grade 3/4 esophagitis using Radiation Therapy Oncology Group criteria. The overall response rate was 52%. Survival rates at 1, 2, 3, and 4 years were 71%, 52%, 40%, and 36%, respectively, with a median survival of 26 months. The 1-, 2-, and 3-year progression free survival probabilities were 47%, 35%, and 29%, respectively. CONCLUSIONS: Incorporation of TCRT with sequential and concurrent carboplatin/paclitaxel is feasible, and dose escalation of TCRT to 74 Gy is possible with acceptable toxicity. Overall response and survival rates are encouraging. Both locoregional and distant failure remain problematic in this population of patients.

Asunto(s)

RESUMEN

1. Arousal from sleep is associated with transient stimulation of ventilation above normal waking levels that predisposes to subsequent breathing instability and central apnoea. The transient hyperpnoea at arousal is normally explained by differences in arterial partial pressure of CO(2) (P(a,CO2)) between sleep and wakefulness, with a higher P(a,CO2) in sleep leading to stimulation of ventilation at arousal according to the awake ventilatory response to CO(2). Surprisingly, however, the validity of this current model in fully explaining the increased ventilation at arousal from sleep has not been directly tested. 2. This study tests the hypothesis that the level of ventilation at arousal from non-rapid eye movement (non-REM) sleep is greater than that produced by elevating P(a,CO2) in wakefulness to the sleeping level, i.e. the ventilation predicted by the current model. 3. Studies were performed in five dogs. Inspired CO(2) was used to increase end-tidal partial pressure of CO(2) (P(ET,CO2)) in wakefulness and measure the ventilatory response. The same P(ET,CO2) was then maintained in non-REM sleep. Ventilation was measured for 10 breaths before and after arousal from non-REM sleep induced by a 72 dB tone. 4. Arousal from sleep produced a transient surge in ventilation of 1.42 +/- 0.35 l min(-1) (P = 0.005). This increased ventilation was due to arousal from sleep per se as the tone alone produced no change in awake ventilation. In support of the hypothesis, ventilation at wake onset from sleep was greater by 0.83 +/- 0.28 l min(-1) (P = 0.031) than the ventilation elicited in wakefulness by raising P(ET,CO2) to the sleeping level. 5. The results show that > 50 % of the increase in ventilation at wake onset from sleep is not attributable to the awake ventilatory response to the elevated P(a,CO2) that was previously present in sleep. This result leads to important modifications of the physiological model currently used to explain the ventilatory consequences of arousal from sleep.

Asunto(s)

RESUMEN

Lung cancer is one of the most lethal cancers, causing more deaths of men and women than any other cancer in the United States. Non-small-cell lung cancers account for most the newly diagnosed cases of lung cancer. Many patients with non-small-cell lung cancer present with advanced-stage disease and are not appropriate candidates for combined modality therapy. Although these patients have incurable disease, they have a chance of achieving improved 1-year survival rates and palliation of symptoms with chemotherapy. The performance status of patients with advanced non-small-cell lung cancer is the most important determinant of response to chemotherapy.

Asunto(s)

RESUMEN

BACKGROUND: A modified Phase I trial was conducted evaluating the incorporation of 3-dimensional conformal radiation therapy (3DCRT) into a strategy of sequential and concurrent carboplatin/paclitaxel in Stage III, unresectable nonsmall cell lung carcinoma (NSCLC). In addition, dose escalation of thoracic conformal radiation therapy (TCRT) from 60 to 74 gray (Gy) was performed. Endpoints included response rate, toxicity, and survival. METHODS: Twenty-nine patients with unresectable Stage III NSCLC were included. Patients received 2 cycles of induction carboplatin (AUC 6) and paclitaxel (225 mg/m(2)/3 hours) every 21 days. On Day 43, concurrent TCRT and weekly (x6) carboplatin (AUC 2) and paclitaxel (45 mg/m(2)/3 hours) was initiated. The TCRT dose was escalated from 60 to 74 Gy in 4 cohorts. RESULTS: The response rate to induction carboplatin/paclitaxel was 52%. Three patients (10%) experienced disease progression during the induction phase. No dose-limiting toxicity was seen during the escalation of the TCRT dose from 60 to 74 Gy. The major toxicity was esophagitis, with 18% of patients developing Radiation Therapy Oncology Group Grade 3 esophagitis. The overall response rate was 70% (1 complete response and 18 partial responses). Survival rates at 1 and 2 years were 69% and 45%, with a median survival of 21 months. The 1-year progression free survival probability was 41% (95% confidence interval, 23-59%). CONCLUSIONS: Incorporation of 3DCRT with sequential and concurrent carboplatin/paclitaxel is feasible, and dose escalation of TCRT to 74 Gy is possible with acceptable toxicity. Overall response and survival rates are encouraging. Accrual is continuing in a Phase II fashion at 74 Gy with sequential and concurrent carboplatin/paclitaxel.

Asunto(s)

RESUMEN

STUDY OBJECTIVES: The physicians who initially evaluate patients with non-small cell lung cancer (NSCLC) strongly impact the course of therapy. Their beliefs in treatment and prognosis may contribute to practices of variable quality and appropriateness. We sought to better describe beliefs among pulmonologists and thoracic surgeons who were selected for guiding early therapy and referrals in patients with NSCLC. DESIGN: Mail questionnaire focusing on survival estimates, treatment perceptions, and referral patterns. PARTICIPANTS: Twelve hundred pulmonologists and 800 thoracic surgeons who were clinically active members of the American College of Chest Physicians. MEASUREMENTS AND RESULTS: Response rates of 50% for pulmonologists and 52% for thoracic surgeons were obtained after two mailings. Five-year survival estimates for patients with resected stage I NSCLC revealed that 30% of respondents overestimated survival rates and 18% underestimated survival rates. The underestimation of survival rate was found among more respondents who are practicing pulmonology than thoracic surgery (22% vs 10% [corrected], respectively), who were trained before 1980 than after 1980 (29% vs 10% [corrected], respectively), and who were seeing < 10 lung cancer patients annually than those who were seeing > 25 (31% vs 0.14%, respectively). Beliefs in the survival benefit of adjuvant chemotherapy or of radiation in stage I-IIIA disease divided respondents within both specialties. Chemotherapy plus radiation vs radiation alone in unresectable stage IIIA-B NSCLC was viewed as benefiting survival less often by physicians seeing < 10 lung cancer patients annually rather than > 25 (57% vs 77% [corrected], respectively) and by physicians underestimating rather than correctly estimating survival in early-stage disease (58% vs 72% [corrected], respectively). Chemotherapy was believed to confer survival benefits in patients with stage IV disease by one third of respondents. CONCLUSIONS: Certain physician characteristics, particularly the length of time since training and NSCLC patient volume, are associated with beliefs not conclusively supported in the medical literature or with opinions inconsistent within and between specialties.

Asunto(s)

RESUMEN

Treatment decisions for non-small-cell lung cancer require accurate initial staging of patients. Typically surgical resection is recommended for early stage disease, while chemotherapy in conjunction with radiotherapy and possibly surgical resection is recommended for selected patients with locally advanced disease. Chemotherapy clearly has been demonstrated to improve survival and quality of life in metastatic disease. Surgical, chemotherapeutic, and radiotherapy treatment options as well as the role of multi-modality therapy will be discussed focusing on the evidence for various stages of non-small-cell lung cancer.

Asunto(s)

RESUMEN

A majority of patients diagnosed with non-small cell lung cancer (NSCLC) will have advanced disease at diagnosis. In the past, systemic therapy (chemotherapy) has demonstrated only slight improvement in survival, hence, practitioners were reluctant to refer patients for cytotoxic therapy. In the past few years, newer chemotherapeutic agents, with increased activity against NSCLC, have been shown to significantly improve median and 1-year survival rates and improve quality of life. Although advanced NSCLC is considered incurable disease, it is, however, potentially treatable disease. This chapter will address the evidence regarding currently available therapies for patients with advanced stage NSCLC.

Asunto(s)

RESUMEN

We report the incidence, clinical features, and course of acute dyspnea following combination chemotherapy using mitomycin and vindesine or vinblastine. The courses of 387 patients with advanced non-small cell lung cancer receiving combined mitomycin and vinca alkaloid chemotherapy were analyzed. Of these patients, 25 experienced acute respiratory distress. Factors contributing to the dyspnea are reported. The syndrome is characterized by the sudden onset of dyspnea without other respiratory symptoms. Acute shortness of breath always occurred on a day when a vinca alkaloid was administered. The median number of previous doses of vinca alkaloid at the time of the event was 10 and the median number of prior mitomycin doses was 3. Rechallenge with the drug in two cases led to recurrence. The incidence was 4% in a group of 378 patients on four protocols for non-small cell lung cancer. Radiographs of 87% of patients showed new focal or diffuse interstitial infiltrates. Arterial blood gases demonstrated low PO2 and increase in A-a gradient. Pulmonary function tests revealed severely impaired diffusing capacity. Substantial improvement occurred over 24 hours. Approximately 60% of the patients experienced chronic respiratory impairment that only partially responded to corticosteroid therapy. No other causes for this syndrome were identified. A syndrome of acute dyspnea occurred in 4% of patients treated with mitomycin and vinca alkaloid therapy. The syndrome has a distinctive presentation, which can lead to chronic pulmonary insufficiency. Clinicians caring for patients receiving combined therapy with mitomycin and a vinca alkaloid should be aware of this type of acute pulmonary toxicity. Further studies are necessary to clarify its etiology.

Asunto(s)

RESUMEN

Presents the application of an instruction package and, through it has been evaluated the efficacy of a health training program for children. By way of the use of this program on the elementary school, we detect the benefit to achieve with it, been compare with a control group, this comparison shows the health education efficacy on the oral prevention. Finally, some recommendations are made for the application of this program.

Asunto(s)

RESUMEN

Results of 235 surveys applied to odontologists performing root canal treatments to ascertain their general knowledge about AIDS. Special emphasis is made on preventive measures they take in their daily practice during handling of the patient, instruments and materials. The most outstanding characteristics of the disease are mentioned and some recommendations set forth for an adequate and safe treatment of the patient at the dentist's office.

Asunto(s)

RESUMEN

This paper describes an epidemiological-clinical study performed at the Iztacala School of Professional Studies, a dependency of the National Autonomous University of Mexico. Records of 2,733 patients treated over a four year period were analyzed so as to examine the relationship between pulp and periodontal diseases, both of which are extremely prevalent in the Mexican population. On the basis of results thus yielded, it was possible to make specific recommendations regarding dental care following diagnosis.

Asunto(s)

RESUMEN

Obesity is a major health problem that can be defined as an excess of body fat, associated with hypertension, diabetes and coronary heart disease. Several groups have evaluated the clinical significance of variations in fat cell distribution on these complications. A frequently used index of fat cell distribution is the waist to hips ratio (W/H). A high W/H ratio is said to reflect upper body fat cell distribution while a low waist to hips ratio reflects a lower body type fat cell distribution. Studies have shown that those whose W/H ratio indicate upper body fat cell distribution had a higher prevalence of diabetes and hypertension than those with the lower type. Over the years cortisol has attracted considerable interest as a possible factor in the development and maintenance of obesity. The clinical findings associated with upper body type of obesity are in many ways similar to those of the hypercortisol state. Our hypothesis is that upper body obesity forms a unique subgroup of the obese population and their regional fat distribution is associated with mild cortisol excess. In humans, studies have reported that some obese subjects hypersecrete cortisol and have an increase in the cortisol production rate. Although recent studies would tend to discount any influence of cortisol in human obesity, several factors should be taken into consideration. It is difficult to measure cortisol economy in obese subjects because among other things the measurements are less than precise; and cortisol secretion changes during the day and in response to outside stimuli. Further, obesity is a heterogeneous disorder and not all obese subjects may have the same disorder.(ABSTRACT TRUNCATED AT 250 WORDS)

Asunto(s)

Asunto(s)

Asunto(s)

Asunto(s)